Company intelligence / Profile preview

SignalChem Lifesciences Corporation

Richmond, British Columbia, Canadasignalchemlifesciences.com ↗

Ownership: Private
Development stage: Other

Overview

Currently conducting clinical trials of AXL inhibitor SLC-391 in combination with KEYTRUDA (pembrolizumab) for advanced or metastatic non-small cell lung cancer. The company has received FDA clearance and Health Canada NOL for this trial.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

slc-391

4 more assets in the full pipeline.

Partnerships

Merck (MSD)Xuanzhu (for SLC-391 in Greater China Region)

Beyond the preview

Go deeper on SignalChem Lifesciences Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignalChem Lifesciences Corporation.